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a b s t r a c t
Background: geno2pheno[coreceptor] is a bioinformatic method for genotypic tropism determination (GTD)
which has been extensively validated.
Objectives: GTD can be affected by sequencing/base-calling variability and unreliable representation
of minority populations in Sanger bulk sequencing. This study aims at quantifying the robustness of
geno2pheno[coreceptor] with respect to these issues. GTD with a single ampliﬁcation or in triplicate (hence-
forth singleton/triplicate) is considered.
Study Design: From a dataset containing 67,997HIV-1 V3 nucleotide sequences, two datasets simulating
sequencing variability were created. Further two datasets were created to simulate unreliable represen-
tation of minority variants. After interpretation of all sequences with geno2pheno[coreceptor], probabilities
of change of predicted tropism were calculated.
Results: geno2pheno[coreceptor] tends to report reduced false-positive rates (FPRs) when sequence alter-
ations are present. Triplicate FPRs tend to be lower than singleton FPRs, resulting in a bias towards
classifying viruses as X4-capable. Alterations introduced into nucleotide sequences by simulation change
singleton predicted tropism with a probability≤2%. Triplicate prediction lowers this probability for
predicted X4 tropism, but raises it for predicted R5 tropism≤6%. Simulated limited detection of minor-
ity variants in X4 sequences resulted in unchanged predicted tropism with probability above 90% as
compared to probability above 98% with triplicate FPRs.
Conclusions: geno2pheno[coreceptor] proved to be robust when sequence alterations are present and when
detectable minorities are missed by bulk sequencing. Changes in tropism prediction due to sequence
alterations as well as triplicate prediction are much more likely to result in false X4-capable predictions
than in false R5 predictions.
© 2015 Published by Elsevier B.V.
1. Background
The Human Immunodeﬁciency Virus type 1 (HIV-1) employs
two host molecules in order to enter the host cell: the CD4 recep-
tor and a coreceptor. In vivo, either of two coreceptors can be:
CCR5 and CXCR4. The capability to use a certain coreceptor is called
Abbreviations: HIV-1, human immunodeﬁciency virus type 1; MVC, maraviroc;
GTD, genotypic tropism determination; FPR, false-positive rate; V3, third hyper-
variable loop; EP, electropherogram dataset; ME, manually-edited sequence; AS,
automatic sequence; SEP, single-electropherogram sequence; indel, insertion or
deletion; LA, Los-Alamos dataset; SA, Sanger-alteration dataset; SE, single-error
dataset; M, mixture dataset; MS, mixture-sampling dataset; CPT, change in pre-
dicted tropism; S, singleton; T, triplicate; SD, standard deviation.
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viral tropism. HIV-1 so-called R5 strains can only use CCR5. CXCR4-
capable strains can use either CXCR4, exclusively (X4 strains), or
both coreceptors (dual/mixed tropic viruses) [1]. Maraviroc (MVC)
is an antiretroviral that inhibits HIV-1 entry into the cell by binding
to CCR5, and is thus ineffective against X4-capable strains. There-
fore, viral tropism determination must precede MVC prescription
[2].
Tropism can be determined phenotypically or genotypically
[3–6]. Phenotypic determination in cell cultures is expensive,
time-consuming, and requires specialized labs. Furthermore, sam-
ples with viral loads up to 1000 cp/ml often yield indeﬁnite
results, although proviral DNA testing is performed also [7]. Geno-
typic tropism determination (GTD) requires genotyping the third
hypervariable loop of the HIV-1 env gene (V3) with subsequent
computer-based interpretation. Several methods for interpret-
ing sequences in order to determine HIV-1 tropism have been
http://dx.doi.org/10.1016/j.jcv.2015.02.006
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developed [6]. geno2pheno[coreceptor] [8] is an extensively validated
bioinformatic method for GTD [3–6,9]; its use as an alternative to
phenotypic determination is recommended by the European and
the Austrian–German HIV-treatment guidelines [12–14].
geno2pheno[coreceptor] interprets V3 with a Support Vec-
tor Machine (SVM) trained on genotype–phenotype pairs.
Geno2pheno[coreceptor] outputs the false-positive rate (FPR)1 with
X4-capable being deﬁned as positive [8]. FPR dichotomization
yields a (predicted) viral classiﬁcation into X4-capable or R5. When
the FPR is in a range where MVC antiviral action is considered
possible, yet uncertain, the virus is classiﬁed as X4-capable. Alter-
natively, this intermediate FPR range can be explicitly labeled, as is
customary for interpretationof drug resistance toother antiretrovi-
ral drugs. Thus,MVCadministrationwithanFPR in the intermediate
range could be made dependent on whether other therapy options
co-exist, rather than excluding it altogether. Furthermore, the use
of an intermediate category when determining tropism can also be
appropriate for predictions with FPR-decreasing sequence alter-
ations, especially when determining tropism in triplicate.
Establishment of the most suitable cutoff for FPR dichotomiza-
tion has been a matter of substantial debate. Currently, there is no
universally accepted cutoff.
2. Objectives
The input to geno2pheno[coreceptor] is aV3 sequence. Therefore,
the quality of the predictions depends on the quality of these
sequences.With Sanger bulk sequencing, themeasured sequence is
a consensus of the dominating strains in the viral population. Here,
minorities comprising less than 10%-20% of the viral population
are unreliably represented, due to the limits of the experimen-
tal technology. X4-capable minorities may render MVC ineffective.
Therefore, some labsperform theampliﬁcation stepof the sequenc-
ing procedure in triplicate [15] to increase the chances of detecting
minorities. This analysis addresses two related, unresolved ques-
tions: (1) How robust is geno2pheno[coreceptor] with respect to
sequencing/base-calling variability in terms of change of predicted
tropism (CPT)? (2) What is the inﬂuence of undetected minor-
ity populations on the predictions of geno2pheno[coreceptor]? Both
issues are of critical importance for assessing the reliability of
geno2pheno[coreceptor] for clinical purposes. This article aims at pro-
viding answers to both questions.
3. Study design
A dataset of 163,958HIV-1 V3 nucleotide sequences
was downloaded from the Los Alamos National Laboratory
(http://www.hiv.lanl.gov/) on September, 19th 2013. Nucleotide
sequences with duplicate V3 regions were discarded, resulting
in the Los-Alamos dataset (LA) comprising 67,997 nucleotide
sequences. Subtypes in LA were determined with Comet [16]. LA
was used to create further datasets by altering its sequences in
silico.
The probability of each type of sequence variation (base
exchanges, ambiguities, insertions/deletions [indels]) at each
sequence position resulting from differential primer speciﬁcity,
and misincorporation/indel events during the RT-PCR ampliﬁca-
tion and sequencing reactions was determined using 164 clinical
blood samples obtained from the Department of Clinical Virology
of theUniversity of Cologne, as described in Section Supplementary
methods. This knowledge was used to generate the Sanger-
alteration dataset (SA). The dataset contains 10 in-silico generated
1 More accurately: it outputs the smallest FPR, of an SVM-classiﬁer that classiﬁes
the sequence under inspection as X4-capable.
variants of each LA sequence. Alterations in these in-silico variants
may be present at any of the 105 nucleotide positions.
The single-error dataset (SE) was created by generating
sequences from each LA sequence by systematically exchanging
every nucleotide in V3 by each of the 15 possible deﬁnite and
ambiguous bases, independently of their probability of occurrence.
Thus, from each sequence in LA, all possible sequences diverging
by one deﬁnite or ambiguous base were generated.
The mixture dataset (M) was created from sequences in LA con-
taining ambiguities (excluding N). Ambiguities in each of these
sequenceswere combinatorially resolved intoall possible sequence
alternatives without ambiguities. To avoid combinatorial explo-
sion, sequences that would result in more than 20,000 derived
sequences were excluded from this procedure.
The mixture-sampling dataset (MS) was created to simulate a
scenario in which sequencing depth is insufﬁcient to resolve all
sequence variants in the sample. From each sequence group in
M derived from the same LA sequence, a certain proportion of
sequences was extracted at random by uniform sampling with-
out replacement, and a new sequence was created by retaining
positions that are identical among the sequences in the subset and
representingdifferential positionswith the corresponding ambigu-
ities. Proportions represent sequencing depth and ranged from 1%
to 100% in steps of 2%; each sequence group was sampled 3×100
times (100 repetitions that allow for triplicate FPRs).
Sequences in LA, SA, SE, M, and MS were interpreted with
geno2pheno[coreceptor]. For each sequence, the FPR shift was cal-
culated as the difference between the FPR of the altered sequence
and that of its unaltered counterpart in LA. When we consider n
FPRs from variability-simulation replicates on the same sequence,
we call singleton FPR the FPR obtained with the ﬁrst sequence. For
all further sequences, we take the minimum FPR among the ﬁrst
n and call it nth replicate FPR. The 3rd replicate FPR is also called
triplicate FPR. geno2pheno[coreceptor]‘s FPR was used to determine
coreceptor tropism as X4-capbable or R5. Four different FPR cutoff
sets were used for tropism determination:
• {5, 10}: FPR<5⇒X4-capable, 5≤ FPR<10⇒ Intermediate,
FPR≥10⇒R5
• {5, 15}: FPR<5⇒X4-capable, 5≤ FPR<15⇒ Intermediate,
FPR≥15⇒R5 [14]
• {10}: FPR<10⇒X4-capable, FPR≥10⇒R5 [13]
• {20}: FPR<20⇒X4-capable, FPR≥20⇒R5 [13]
According to Austrian–German treatment guidelines, MVC can
be effective when a tropism prediction is labeled intermediate
albeit with much less certainty than for R5 variants [14].
The probability the tropism predicted by geno2pheno[coreceptor]
changed due to the introduced sequence alterations was calcu-
lated by sample counting as P(TA,C | TU,C), with TA,C denoting the
tropism of the altered sequences as determined with cutoff set C,
and TU,C denoting the tropism of the unaltered sequences as deter-
mined with cutoff set C. The reference sequence used to number
V3 nucleotide positions is consensus B (105 nucleotides), which is
the reference used by geno2pheno[coreceptor].
4. Results
Alteration rates estimated for generation of SA (Section
Supplementarymethods) are shown inSupplementaryTables1and
2.
The FPR distribution in LA is illustrated in Supplementary Fig.
1. The numbers of strains by subtype are tabulated in Table 1. In
LA, 0.24% of the bases are ambiguous, while 99.76% of the bases are
deﬁnite.
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Table 1
Numberof strainsby subtype, circulating recombinant formorgroup, LAdataset.The
numbers of strains of each subtype, circulating recombinant form (CFR) or group in
the LA dataset are tabulated above.
Subtype, CRF or Group Number of strains
B 35312
C 11056
A1 10187
01 AE 4986
D 2691
G 1422
F1 1308
F2 324
O 226
A2 207
H 121
CPZ 68
J 46
K 27
N 11
P 5
Among the FPR shifts between the altered SA sequence and
that of its unaltered counterpart in LA, 79% are equal to zero, 11%
are below zero and 10% are above zero (see also Supplementary
Fig. 2). Fig. 1 shows how the probability of obtaining FPRs lower
than the singleton FPR increases with the number of ampliﬁca-
tions. Finally, Figs. 2 and 3 depict the change of predicted tropism
(CPT) probabilities for different cutoff sets (probabilities labeled S
for singleton FPRs and T for triplicate FPRs). Figs. 2 and 3 show
that geno2pheno[coreceptor] is more likely to reduce than to raise
FPR when sequence alterations are present, slightly favoring a false
prediction of R5 viruses as X4-capable over the reverse mispredic-
tion (see also Supplementary Fig. 2). Since the FPR shifts are both
negative and positive, FPR determination in triplicate will always
reduce FPRs, as the minimum FPR is selected. When determining
FPR in triplicate, there is a 27% chance that the triplicate FPR will
be lower than the singleton FPR (Fig. 1).
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Fig. 1. Probabilities of decreasing FPR as more replicates are performed. FPRs in
SA dataset were compared with their unaltered counterparts in the LA dataset. The
probabilities of obtaining nth replicate FPRs lower than the singleton FPRs are plot-
ted with increasing values for n (replicate number) in the chart above (Color/BW).
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a) Cutoﬀ: 10
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M: 0.88
MSS: 0.91
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M: 0.85
MSS: 0.95
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M: 0.15
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Fig. 2. Conditional probabilities of change in predicted tropism, cutoff sets {10} and
{20}: Cutoff sets {10} and {20} were applied to FPRs in LA, SA, M, and MS datasets
to calculate the conditional probabilities of CPT. Results are shown for SA dataset
singleton (S), SAdataset triplicate (T),Mdataset (M),MSdataset singleton (MSS), and
MS dataset triplicate (MST) FPRs. There are no replicates on the M dataset since its
sequences contain no ambiguities. The circles in the ﬁgure represent the predicted
tropism. The arrows indicate a change in predicted tropism with the head of the
arrowpointing towards the change. Thearrow labels contain theprobabilities for the
respective changes in predicted tropism as calculated with the dataset mentioned
above (Color/BW).
The overall average shift in SE is −2.22 (SD=13.87); 23% of
these shifts are zero, 36% are above zero and 40% are below
zero (Supplementary Fig. 3). Here again we see the tendency
of geno2pheno[coreceptor] to reduce FPR when sequence alter-
ations are present. Fig. 4 shows a plot of FPR shifts averaged by
nucleotide position. Alterations in some parts of the V3 loop have
a higher propensity for changing coreceptor tropism than others,
as expected. The magnitude and sign of the average shifts vary
greatly with the nucleotide position. Shifts averaged by nucleotide
or ambiguity code can be seen in Table 2.
In LA, 6133 sequences contained ambiguous bases. The
sequences in the M dataset were derived from 6118 of these
sequences by resolving their ambiguities. Fifteen sequences were
excluded to avoid combinatorial explosion. Among the 6133 orig-
inal sequences, 41% resulted in two derived sequences while 59%
resulted in more than two sequences (Supplementary Fig. 4). Sup-
plementary Fig. 5 shows a plot of the average shift in MS against
the sampling proportion, for triplicate and for singleton FPRs. The
magnitude of the shift decreases as the proportion increases, and
was zero for proportions of 85% of the sequences or more. The low-
est proportion tested, 1%, yielded a mean singleton FPR shift of
0.61 (SD=10.91), and amean triplicate FPR shift of −4.5 (SD=9.35).
Since conditional CPT probabilities decrease as the sampling pro-
portion increases, Figs. 2 and 3 only display those for sampling 1%
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Fig. 3. Conditional probabilities of change in predicted tropism, cutoff sets {5,10}
and {5,15}: Cutoff sets {5,10} and {5,15} were applied to FPRs in LA, SA, M, and
MS datasets to calculate the conditional probabilities of CPT. Results are shown
for SA dataset singleton (S), SA dataset triplicate (T), M dataset (M), MS dataset
singleton (MSS), and MS dataset triplicate (MST) FPRs. There are no replicates on
the M dataset since its sequences contain no ambiguities. The circles in the ﬁgure
represent the predicted tropism. The arrows indicate a change in predicted tropism
with the head of the arrow pointing towards the change. The arrow labels contain
the probabilities for the respective changes in predicted tropism as calculated with
the dataset mentioned above (Color/BW).
of the variants in M, labeled MSS for singleton FPRs and MST for
triplicate FPRs. CPT probabilities calculated with all the sequences
in M are also displayed in Figs. 2 and 3 (probabilities labeled M).
5. Discussion
This analysis addresses two related questions: the robustness
of geno2pheno[coreceptor] with respect to sequence alterations in
terms of change of predicted tropism, and the inﬂuence of minority
populations on the predictions of geno2pheno[coreceptor]. Therefore,
we have subjected geno2pheno[coreceptor] to a challenge involving
the systematic introduction of simulated sequencing variability
into a large set of V3 nucleotide sequences in order to gen-
erate four datasets: SA simulates alterations due to the Sanger
Table 2
Mean FPR shift averaged by nucleotide base, SE dataset.The table shows the mean
FPR shift and standard deviation (SD), averaged by substituting nucleotide base after
alignment. Shifts were calculated by comparing FPRs in the SE dataset with their
unaltered counterparts in the LA dataset. Although gaps were not considered when
generating the SE dataset, some nucleotide alterations were transformed to gaps by
the alignment program of geno2pheno[coreceptor] .
IUPAC base Mean SD
A −3.33 20.01
C −1.77 17.98
G −4.85 17.49
T −2.40 18.33
B −2.57 12.98
D −2.18 12.12
H −1.77 13.26
K −2.65 12.94
M −1.88 13.35
N −2.19 12.50
R −2.86 12.72
S −2.89 13.06
V −2.42 12.26
W −1.63 13.12
Y −1.20 14.25
– 0.26 18.07
sequencing technique. SE explores the effects of systematically
introduced single nucleotide exchanges. With M and MS we inves-
tigated the inﬂuence of simulated viral minorities undetected by
bulk sequencing.
An accurate study of the effect of sequencing X4-associated
codons at amino-acid positions 11, 13, 24, 25, and 32 (nucleotide
positions 30–33, 37–39, 69–72, 73–75, 94–96) more accurately
by using speciﬁc primers has been studied[17]. The primer sets
were speciﬁcally designed for subtype B. Our study has extended to
other subtypes, as about half of the 67,997 sequences were non-Bs
(Table 1).
The FPR shifts between the original and the in-silico mutated
sequences in SE have been analyzed (Fig. 4 and Table 2). 9.1% are
less than −20 and 11% are greater than 10. These two shift val-
ues were chosen to be multiples of 10, close to the 10th and 90th
percentile of the shift distribution. The shift cutoff −20 identiﬁes
amino-acid positions 7, 8, 11 (nucleotide positions 19–21, 22–24,
31–33), and insertions after amino-acid positions 21, 22 and 23
(nucleotide positions 61–63, 64–66 and 67–69) as highly relevant
for detection of CXCR4-capable viruseswith geno2pheno[coreceptor].
Using a shift cutoff of 10, positions 9, 10, 17, 28 and 31 (nucleotide
positions 25–27, 28–30, 48–51, 82–84, 91–93) are highly rele-
vant for the detection of R5 viruses with geno2pheno[coreceptor].
Mean shifts averaged by nucleotide base are negative, unless the
sequence alteration is replaced with a gap by the alignment pro-
gram. The smallest mean shift is −4.85. These results indicate that
the position at which the alteration occurs is far more important
than the nucleotide base the alteration consists of, as might have
been expected.
Triplicate sequencing is performed with the intention of
improving the detection of X4-capable minority variants. In trip-
licate testing, the lowest FPR is considered the correct one, without
comparing the obtained nucleotide sequences. Thus, if the lowest
FPR is caused by a nucleotide sequencing error, triplicate test-
ing will bias the prediction towards favoring X4-capable. If the
obtained sequences are not manually inspected, errors in the indi-
vidual sequences remain undetected. Thus, the more replications
are sequenced, the higher the chance you get an FPR lower than the
ﬁrst one, even if X4-capable minority variants are absent. In this
case, triplicate testing can result in an exclusion of MVC-eligible
patients, without increasing the safety of the prediction.
Figs. 2 and 3 show the inﬂuence of introduced variability for
change of predicted tropism depending on the FPR cutoffs, for both
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Fig. 4. Mean FPR shifts averaged by nucleotide position, SE Dataset. The graphic above shows the mean shift in the FPR averaged by nucleotide position. Shiftswere calculated
by comparing FPRs in the SE dataset with their unaltered counterparts in the LA dataset. Each bar represents a nucleotide position; its height indicates the mean FPR shift
resulting from an alteration at that position. Error bars show standard deviation. Insertions are labeled with the preceding nucleotide position, the character “I” and an index
(Color/BW).
single and triplicate testing. geno2pheno[coreceptor] is robust when
introduced variability is present: for all cutoff sets, the probability
of no CPT is above 98% (or above 93% if the intermediate tropism
prediction is considered) for singleton FPRs. In this scenario, tripli-
cate FPRs raise the probability that predicted X4 capability will not
change by up to 2%, but reduce the probability that predicted R5
tropism will not change by up to 4%.
To address the study of minorities, we created the M and MS
datasets. M contains the variants from which the sequence with
ambiguities could have arisen, but might also contain variants
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absent in the sample. In contrast, MS presents a more realistic pic-
ture, since a sequence that may contain ambiguities is constructed
from a sample of the sequences in M representing the limited
sequencingdepthof anexperiment. For the smallest fraction tested,
1%, the probability predicted X4 tropism does not change is ≥90%
with singleton FPRs, and 98% with triplicate FPRs. Thus, triplicate
FPRs raise the probability predicted X4 tropism does not change by
9%, at most, for the lowest tested proportion (Figs. 2 and 3).
The lowest valueobtained for theprobability that there is noCPT
is 90% with geno2pheno[coreceptor]. In order to put this number into
context, we mention Troﬁle’s reported sensitivity to detect MVC
responders, 92% [11].
geno2pheno[coreceptor] proved to be robust in the presence of
sequence alterations and when detectable minorities are missed
by bulk sequencing. False R5 predictions were either rare or absent
in our analysis, depending on the selected cutoffs. If a CPT occurs,
it is much more likely that sequence alterations result in false X4-
capable predictions than false R5 predictions. This speaks for the
safety of MVC prescription to patients with predicted R5 viruses.
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